Search

Displaying results 1851 - 1860 of 5263 in total
  1. Drug

    Favipiravir

    go.drugbank.com/drugs/DB12466
    ApprovedInvestigational

    [A191688,A191772,A191775] Not only does favipiravir inhibit replication of influenza A and B, but the drug has shown promise in the treatment of avian influenza, and may be an alternative option for … Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza.

  2. Drug

    Pralsetinib

    go.drugbank.com/drugs/DB15822
    ApprovedInvestigational

    It is currently marketed under the brand name GAVRETO™ by Blueprint Medicines.[L15986]

  3. Drug

    Teniposide

    go.drugbank.com/drugs/DB00444
    ApprovedInvestigational

    Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle. … Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding.

  4. Drug

    Nintedanib

    go.drugbank.com/drugs/DB09079
    ApprovedInvestigational

    Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC). It was first approved for use in the United Sta...

    Synonyms: methyl (3Z)-3-[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}anilino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylate
  5. Drug

    Rurioctocog alfa pegol

    go.drugbank.com/drugs/DB16007
    ApprovedInvestigational

    [L40119] Rurioctocog alfa pegol is a covalent conjugate of [octocog alfa], which is a recombinant factor VIII produced by recombinant DNA technology from a Chinese hamster ovary cell line. … It was first approved by the European Commission in January 2018.

  6. Drug

    Temafloxacin

    go.drugbank.com/drugs/DB01405
    ApprovedWithdrawn

    It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three

  7. Drug

    Fluoride ion F-18

    go.drugbank.com/drugs/DB09398
    ApprovedInvestigational

    It contains radioactive fluoride F 18 that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging and is administered by intravenous injection. … No adverse reactions have been reported.

  8. Drug

    Perboric acid

    go.drugbank.com/drugs/DB13235
    Approved

    [F66] Perboric acid in the form of sodium perborate is approved by Health Canada since 2004 to be used as a disinfectant of medical instruments. … [L1113] By the FDA, sodium perborate is approved as an ointment for the protection of poison ivy dermatitis.[L2764]

  9. Target

    Inactive phospholipase C-like protein 1

    go.drugbank.com/bio_entities/BE0001081
    TargetHumans

    Involved in an inositol phospholipid-based intracellular signaling cascade. Shows no PLC activity to phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol. Component in the phospho-dependent endocytosis process of GABA A recepto...

    Synonyms: Phospholipase C-related but catalytically inactive protein
  10. Drug

    Dorocubicel

    go.drugbank.com/drugs/DB19448
    Approved

    Dorocubicel is a preparation of cryopreserved allogeneic umbilical cord-derived hematopoietic stem cells and blood progenitors expanded ex vivo using UM-171. It is one component of a cell therapy, Zemcelpro, that also contains unexpanded...